ArticleMolecular cancer therapeutics2025

The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer.

Megharani Mahajan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.